Lubbe W F
S Afr Med J. 1977 Nov 26;52(23):913-8.
Prazosin (Minipress; Pfizer), a new antihypertensive agent, was investigated in 24 outpatients with uncontrolled hypertension. In 12 patients a single-blind placebo-controlled trial was conducted and in 12 patients an open trial with treatment for a minimum of 16 weeks. Three patients developed postural hypotension and were withdrawn from the trial. Fifteen patients responded to treatment with prazosin and normotensive levels were reached in 9. Ten patients had renal impairment at the start of the study; renal function remained static in 9 and serum urea and creatinine values increased in 1. Prazosin maintains renal function well in severely hypertensive patients and has a relatively low incidence of side-effects, related mainly to postural hypotension which develops unpredictably in some patients. In addition to its extensively documented beneficial effect in mild and moderate forms of hypertension, prazosin is of use in the therapy of patients with severe and uncontrolled hypertension.
哌唑嗪（脉宁平；辉瑞公司）是一种新型抗高血压药物，对24例高血压控制不佳的门诊患者进行了研究。对12例患者进行了单盲安慰剂对照试验，对另外12例患者进行了至少16周治疗的开放试验。3例患者出现体位性低血压，退出试验。15例患者对哌唑嗪治疗有反应，9例血压恢复正常。10例患者在研究开始时有肾功能损害；9例肾功能保持稳定，1例血清尿素和肌酐值升高。哌唑嗪对重度高血压患者肾功能维持良好，副作用发生率相对较低，主要与体位性低血压有关，部分患者会不可预测地发生。除了在轻、中度高血压中广泛记录的有益作用外，哌唑嗪还可用于治疗重度和血压控制不佳的高血压患者。
